X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   TEVA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
TEVA PHARMA
Dec-13
ALKEM LABORATORIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5892,709-   
Low Rs1,2322,353-   
Sales per share (Unadj.) Rs417.51,554.5-  
Earnings per share (Unadj.) Rs56.397.1-  
Cash flow per share (Unadj.) Rs64.7222.8-  
Dividends per share (Unadj.) Rs12.7085.01-  
Dividend yield (eoy) %0.93.4 26.8%  
Book value per share (Unadj.) Rs292.91,726.7-  
Shares outstanding (eoy) m119.57848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.6 207.5%   
Avg P/E ratio x25.126.1 96.1%  
P/CF ratio (eoy) x21.811.4 191.9%  
Price / Book Value ratio x4.81.5 328.5%  
Dividend payout %22.687.5 25.8%   
Avg Mkt Cap Rs m168,6532,146,042 7.9%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM29,328.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM1,832.1-  
INCOME DATA
Net Sales Rs m49,9151,318,175 3.8%  
Other income Rs m1,6450-   
Total revenues Rs m51,5611,318,175 3.9%   
Gross profit Rs m8,482360,983 2.3%  
Depreciation Rs m1,006106,549 0.9%   
Interest Rs m67125,891 2.6%   
Profit before tax Rs m8,451228,543 3.7%   
Minority Interest Rs m-1141,038 -11.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-150,026 0.0%   
Tax Rs m1,606-2,790 -57.6%   
Profit after tax Rs m6,73182,345 8.2%  
Gross profit margin %17.027.4 62.1%  
Effective tax rate %19.0-1.2 -1,556.5%   
Net profit margin %13.56.2 215.9%  
BALANCE SHEET DATA
Current assets Rs m27,062890,291 3.0%   
Current liabilities Rs m15,324776,409 2.0%   
Net working cap to sales %23.58.6 272.2%  
Current ratio x1.81.1 154.0%  
Inventory Days Days6791 73.2%  
Debtors Days Days4196 43.0%  
Net fixed assets Rs m12,610430,545 2.9%   
Share capital Rs m2393,245 7.4%   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,0271,464,243 2.4%   
Long term debt Rs m1,212674,012 0.2%   
Total assets Rs m54,3873,012,453 1.8%  
Interest coverage x13.69.8 138.4%   
Debt to equity ratio x00.5 7.5%  
Sales to assets ratio x0.90.4 209.7%   
Return on assets %13.63.6 378.8%  
Return on equity %19.25.6 341.7%  
Return on capital %24.94.9 504.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,259210,049 3.5%  
From Investments Rs m1,864-74,429 -2.5%  
From Financial Activity Rs m-9,273-251,968 3.7%  
Net Cashflow Rs m-150-116,348 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare ALKEM LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare ALKEM LABORATORIES With: DIVIS LABORATORIES  ALEMBIC LTD  TTK HEALTHCARE  CIPLA  GSK PHARMA  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS